Sugi Predict

Sugi Predict / Compounds / SCHEMBL10063820

SCHEMBL10063820

SCHEMBL10063820

COc1cc2cc(c1Cl)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)[C@]1(C)O[C@H]1[C@H](C)C1C[C@@](O)(NC(=O)O1)[C@H](OC)/C=C/C=C(\C)C2

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TUBB4A P04350 4/20 0.83
▸ TUBB P07437 4/20 0.83
▸ TUBA3C P0DPH7 4/20 0.83
▸ TUBA1B P68363 4/20 0.83
▸ TUBA4A P68366 4/20 0.83
▸ TUBB4B P68371 4/20 0.83
▸ TUBB3 Q13509 4/20 0.83
▸ TUBB2A Q13885 4/20 0.83
▸ TUBB8 Q3ZCM7 4/20 0.83
▸ TUBA3E Q6PEY2 4/20 0.83
▸ TUBA1A Q71U36 4/20 0.83
▸ TUBA1C Q9BQE3 4/20 0.83
▸ TUBB6 Q9BUF5 4/20 0.83
▸ TUBB2B Q9BVA1 4/20 0.83
▸ TUBB1 Q9H4B7 4/20 0.83
▸ CYP2D6 P10635 1/20 0.79
▸ TSHR P16473 1/20 0.79
▸ CYP2C19 P33261 1/20 0.79
▸ HIF1A Q16665 1/20 0.79
▸ P4HB P07237 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12530622 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL22651647 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL22372700 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL22580752 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL21127723 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL16128978 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13667605 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL21729001 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL20822457 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL17349736 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364252-A1 METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS IMMUNOGEN SWITZERLAND GMBH (CH) 2023-11-16 — — US disclosed
US-20230287137-A1 CD37-BINDING MOLECULES IMMUNOCONJUGATES THEREOF IMMUNOGEN, INC. 2023-09-14 — — US disclosed
US-20230190638-A1 ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS IMMUNOGEN, INC. 2023-06-22 — — US disclosed
US-11572411-B2 Anti-CD117 antibodies and conjugates Magenta Therapeutics, Inc. (US) 2023-02-07 — — US disclosed
US-20220249683-A1 T-CELL DEPLETING THERAPIES HEIDELBERG PHARMA RESEARCH GMBH (DE) 2022-08-11 — — US disclosed
US-11395796-B2 Anti-CD37 immunoconjugate and anti-CD20 antibody combinations DEBIOPHARM INTERNATIONAL, S.A. (CH) 2022-07-26 — — US disclosed
US-20220177578-A1 ANTI-CD117 ANTIBODIES AND USES THEREOF Magenta Therapeutics, Inc. 2022-06-09 — — US disclosed
US-20220175946-A1 CONDITIONING METHODS FOR GENE THERAPY REGENERON PHARMACEUTICALS, INC. 2022-06-09 — — US disclosed
US-20220177575-A1 ANTI-CD117 ANTIBODIES AND USES THEREOF Magenta Therapeutics, Inc. 2022-06-09 — — US disclosed
US-20220168326-A1 THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES IMMUNOGEN SWITZERLAND GMBH (CH) 2022-06-02 — — US disclosed
US-20130295104-A1 CD37-Binding Molecules and Immunoconjugates Thereof DEBIOPHARM INTERNATIONAL, S.A. (CH) 2013-11-07 — — US disclosed
US-8557966-B2 Folate receptor 1 antibodies and immunoconjugates and uses thereof IMMUNOGEN, INC. (US) 2013-10-15 — — US disclosed
US-20130156796-A1 Method of Treatment of Tumors That Are Resistant to EGFR Therapies by EGFR Antibody Cytotoxic Agent Conjugate IMMUNOGEN, INC. 2013-06-20 — — US disclosed
US-20120282282-A1 Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates IMMUNOGEN, INC. (US) 2012-11-08 — — US disclosed
US-20120276119-A1 CD37-Binding Molecules and Immunoconjugates Thereof DEBIOPHARM INTERNATIONAL, S.A. (CH) 2012-11-01 — — US disclosed
US-20120156217-A1 Novel EGFR-Binding Molecules and Immunoconjugates Thereof IMMUNOGEN, INC. 2012-06-21 — — US disclosed
US-20120009181-A1 Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof IMMUNOGEN SWITZERLAND GMBH (CH) 2012-01-12 — — US disclosed
US-20110256153-A1 CD37-Binding Molecules and Immunoconjugates Thereof DEBIOPHARM INTERNATIONAL, S.A. (CH) 2011-10-20 — — US disclosed
US-20110195022-A1 CD20 ANTIBODIES AND USES THEREOF IMMUNOGEN INC. (US) 2011-08-11 — — US disclosed
US-20110195021-A1 CD20 ANTIBODIES AND USES THEREOF IMMUNOGEN INC. (US) 2011-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110256153-A1 CD37-Binding Molecules and Immunoconjugates Thereof SIGLEC7, FUT7, CD2BP2 TUBB4A 1511/4885TUBB 1767/4885TUBA3C 1873/4885
US-20220177575-A1 ANTI-CD117 ANTIBODIES AND USES THEREOF MYADM, SIGLEC7, ITGB7 TUBB4A 772/4885TUBB 604/4885TUBA3C 464/4885
US-11572411-B2 Anti-CD117 antibodies and conjugates ITGB7, FUT7, CD2 TUBB4A 426/4885TUBB 377/4885TUBA3C 291/4885
US-20130156796-A1 Method of Treatment of Tumors That Are Resistant to EGFR Therapies by EGFR Antibody Cytotoxic Agent Conjugate EGFR, ALK, ERBB2 TUBB4A 453/4885TUBB 393/4885TUBA3C 526/4885
US-20120156217-A1 Novel EGFR-Binding Molecules and Immunoconjugates Thereof EGFR, ERBB2, ERBB4 TUBB4A 428/4885TUBB 534/4885TUBA3C 755/4885
US-20130295104-A1 CD37-Binding Molecules and Immunoconjugates Thereof SIGLEC7, FUT7, CD2BP2 TUBB4A 1511/4885TUBB 1767/4885TUBA3C 1873/4885
US-11395796-B2 Anti-CD37 immunoconjugate and anti-CD20 antibody combinations CD209, SIGLEC7, SIGLEC9 TUBB4A 3006/4885TUBB 3142/4885TUBA3C 3186/4885
US-20120009181-A1 Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof FOLR1, FOLR2, DHFR TUBB4A 1450/4885TUBB 1270/4885TUBA3C 2129/4885
US-20110195021-A1 CD20 ANTIBODIES AND USES THEREOF BCL9, BCL9L, BCL6B TUBB4A 926/4885TUBB 689/4885TUBA3C 2539/4885
US-20230190638-A1 ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS CD209, SIGLEC7, SIGLEC9 TUBB4A 3006/4885TUBB 3142/4885TUBA3C 3186/4885
US-20120282282-A1 Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates UACA, CYTH3, FCGR2A TUBB4A 125/4885TUBB 64/4885TUBA3C 89/4885
US-20220177578-A1 ANTI-CD117 ANTIBODIES AND USES THEREOF MYADM, SIGLEC7, ITGB7 TUBB4A 772/4885TUBB 604/4885TUBA3C 464/4885
US-20110195022-A1 CD20 ANTIBODIES AND USES THEREOF BCL9, BCL9L, BCL6B TUBB4A 926/4885TUBB 689/4885TUBA3C 2539/4885
US-20220175946-A1 CONDITIONING METHODS FOR GENE THERAPY CD74, CD2, CD44 TUBB4A 1148/4885TUBB 742/4885TUBA3C 1082/4885
US-20220249683-A1 T-CELL DEPLETING THERAPIES CD2, CD4, CD22 TUBB4A 958/4885TUBB 1278/4885TUBA3C 724/4885
US-20230287137-A1 CD37-BINDING MOLECULES IMMUNOCONJUGATES THEREOF SIGLEC7, CD2BP2, FUT7 TUBB4A 1423/4885TUBB 1677/4885TUBA3C 1810/4885
US-20220168326-A1 THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES FOLR1, FOLR2, DHFR TUBB4A 1496/4885TUBB 1134/4885TUBA3C 887/4885
US-20120276119-A1 CD37-Binding Molecules and Immunoconjugates Thereof SIGLEC7, CD2, CD22 TUBB4A 3507/4885TUBB 3646/4885TUBA3C 3889/4885
US-20230364252-A1 METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS FCGRT, FCGR1A, FCGR3B TUBB4A 1047/4885TUBB 798/4885TUBA3C 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback